Article
type: Class

Document
type: Class

Information Content Entity
type: Class

Academic Article
type: Class

Continuant
type: Class

Entity
type: Class

RDF description of Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? - http://irises.unisr.it/resource/item/98953
rights: termsOfUse
date: 2026-08-24T20:39:34
publisher: Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
type: Document

Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
type: Entity
most specific type: Academic Article
type: Generically Dependent Continuant
type: Document
type: Article
type: Academic Article
type: Information Content Entity
related by: 5494412
type: Thing
type: Continuant

Generically Dependent Continuant
type: Class

5494412
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?